Vimarsana
Biggest News Aggregation in the World

Page 12 - Poster Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Poster Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Poster Presentation Today - Breaking & Trending Today

Live from ASCO 2023 | For the Third Consecutive Year, Ascentage Pharma Releases Promising Results of Alrizomadlin plus Pembrolizumab in Patients with Cutaneous Melanoma that Failed Immuno-Oncologic (IO) Therapies - Vimarsana News

Live from ASCO 2023 | For the Third Consecutive Year, Ascentage Pharma Releases Promising Results of Alrizomadlin plus Pembrolizumab in Patients with Cutaneous Melanoma that Failed Immuno-Oncologic (IO) Therapies

Published: June 5, 2023

SUZHOU, China, and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a Phase II study of MDM2-P53 inhibitor, alrizomadlin (APG-115), in combination with pembrolizumab in patients with unresectable or...

Source: asiaone.com
Related Topics:
United StatesSan AntonioUniversity Of TexasWestern AustraliaHong KongAscentage PharmaYifan ZhaiPrnewswire Ascentage PharmaMontaserf ShaheenMd Anderson Cancer CenterMajor NationalDana Farber Cancer InstituteChina National Medical Products AdministrationUniversity Of Texas Health Science CenterAmerican Society Of Clinical OncologyNational Reimbursement Drug ListPoster PresentationAmerican SocietyClinical OncologyPrincipal InvestigatorTexas Health Science CenterChief Medical OfficerCancer StatisticsMortality WorldwideMain Board
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 - Vimarsana News

Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

Published: June 1, 2023

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

Source: prnewswire.com
Related Topics:
United StatesRobert KaniaGraeme CurrieLindsay KilburnExchange CommissionWade Clapp At Indiana UniversityMarket ResearchDevelopment OfficerChildren National HospitalFn Media GroupKinnate Biopharma IncSecurities ExchangeAmerican Society Of Clinical OncologySchool Of MedicineSpringworks Therapeutics IncPasithea Therapeutics CorpCoherent Market InsightsActive BiotechsPasithea TherapeuticsSpringworks TherapeuticsDay One BiopharmaceuticalsVerastem OncologyKinnate BiopharmaMaximize Market ResearchNeurofibromatosis Treatment Market
Financialnewsmedia.com: Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 - Vimarsana News

Financialnewsmedia.com: Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

Published: June 1, 2023

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 1, 2023 /PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing

Source: finanznachrichten.de
Related Topics:
United StatesLindsay KilburnRobert KaniaGraeme CurrieMarket ResearchSpringworks Therapeutics IncSecurities ExchangeAmerican Society Of Clinical OncologyFn Media GroupDevelopment OfficerChildren National HospitalWade Clapp At Indiana UniversityKinnate Biopharma IncSchool Of MedicinePasithea Therapeutics CorpExchange CommissionCoherent Market InsightsPasithea TherapeuticsSpringworks TherapeuticsDay One BiopharmaceuticalsVerastem OncologyKinnate BiopharmaMaximize Market ResearchNeurofibromatosis Treatment MarketBreaking News
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types - Vimarsana News

New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types

Published: May 30, 2023

Highlights include oral presentations in Sarcoma and CRC; immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study; updates from the CIRCULATE-Japan study in CRC ... | May 30, 2023

Source: marketscreener.com
Related Topics:
United StatesSan CarlosAmerican Society Of Clinical OncologyNatera IncClinical Laboratory Improvement AmendmentsAssociation Of TumorClinical OncologyAnnual MeetingMinetta LiuPoster DiscussionHigh RatesUndiagnosed Concomitant Radiographic RecurrencesOral PresentationSoft Tissue SarcomaPoster PresentationClinical OutcomesMuscle Invasive Bladder CancerMulticenter Retrospective Real WorldEsophageal CancerInforms Maintenance OutcomesBile Duct CancerPancreatic CancerThymus CancerBreakthrough Device DesignationsNc Stock Exchange
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting - Vimarsana News

Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting

Published: May 8, 2023

CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--May 8, 2023--

Source: cadillacnews.com
Related Topics:
United StatesUnited KingdomLindsay YanekCarlo TanziUs Bureau Of Labor StatisticsHealth ScienceAimmune Therapeutics IncSociety For Surgery Of The Alimentary TractExchange CommissionCenters For DiseaseUs Bureau Of Labor StatisticsUrgent Health ThreatAmerican Gastroenterological AssociationDrug AdministrationAmerican Society For Gastrointestinal EndoscopySeres Therapeutics IncDisease WeekAnnual MeetingChief Medical OfficerBreakthrough TherapyOrphan Drug DesignationsNew England JournalClinical ResponseInvestigational Oral Microbiome TherapeuticLabel Trial